{
    "clinical_study": {
        "@rank": "89260", 
        "brief_summary": {
            "textblock": "To evaluate topical A-007 in patients with advanced malignancies including Kaposi's sarcoma\n      and lymphoproliferative disorders."
        }, 
        "brief_title": "Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders", 
        "condition": [
            "Sarcoma, Kaposi", 
            "HIV Infections", 
            "Lymphoproliferative Disorders"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Lymphoproliferative Disorders", 
                "Sarcoma, Kaposi", 
                "Sarcoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Maintenance antihormones, hormones, and glucocorticoids.\n\n        Patients must have:\n\n          -  Histologically proven metastatic cancer including Kaposi's sarcoma and\n             lymphoproliferative disorders to the skin or cutaneous sites. NOTE:\n\n          -  Primary basal or squamous cell cancer of the skin is allowed.\n\n          -  Failed both primary and secondary chemotherapy and/or immunotherapy protocols.\n\n          -  Measurable skin or cutaneous lesions. 4 Life expectancy of at least 20 weeks.\n\n        Prior Medication:\n\n        Required:\n\n          -  Prior therapy for cutaneous lesions from Kaposi's sarcoma or lymphoproliferative\n             disorders.\n\n        Allowed:\n\n          -  Prior maintenance steroids and hormone/antihormone therapy.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Active infections other than medically stable HIV infection.\n\n          -  Active congestive heart failure, any persistent arrhythmia or transient serious\n             arrhythmia (ventricular tachycardia, sinoatrial arrest, etc.), or progressive\n             cardiomyopathy.\n\n          -  Unstable blood pressure.\n\n          -  Seizures or other CNS disorders.\n\n          -  Severe unstable diabetes mellitus.\n\n          -  Coagulopathies.\n\n          -  Thrombotic disease.\n\n          -  Any other medical conditions that would prevent completion of study or produce\n             significant risk to patient.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Concomitant chemotherapy or immunotherapy.\n\n          -  Ongoing corticosteroid therapy (unless maintenance).\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of active cardiopulmonary or respiratory disease.\n\n          -  History of sun hypersensitivity and photosensitive dermatoses.\n\n          -  History of allergy or hypersensitivity to cosmetics, toiletries, or other\n             dermatological products."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": "25", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002153", 
            "org_study_id": "247A", 
            "secondary_id": "DTI-006"
        }, 
        "intervention": {
            "intervention_name": "A-007", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Antineoplastic Agents"
        }, 
        "keyword": [
            "Skin Neoplasms", 
            "Sarcoma, Kaposi", 
            "Acquired Immunodeficiency Syndrome", 
            "Antineoplastic Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "New Orleans", 
                    "country": "United States", 
                    "state": "Louisiana", 
                    "zip": "70119"
                }, 
                "name": "DEKK - TEC Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002153"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "DEKK-TEC, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 1999"
    }, 
    "geocoordinates": {
        "DEKK - TEC Inc": "29.951 -90.072"
    }
}